menu
    • menu
    [{"orgOrder":0,"company":"Kedalion Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Lifitegrast","moa":"Integrin alpha-L\/beta-2 (LFA-1)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Kedalion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Kedalion Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Kedalion Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Lifitegrast","moa":"Integrin alpha-L\/beta-2 (LFA-1)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Lifitegrast","moa":"Integrin alpha-L\/beta-2 (LFA-1)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":2.5,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":2.5,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Lifitegrast","moa":"Integrin alpha-L\/beta-2 (LFA-1)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":2.5,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":2.5,"dosageForm":"Ophthalmic Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"University of Waterloo","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lifitegrast","moa":"Integrin alpha-L\/beta-2 (LFA-1)","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"University of Waterloo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"University of Waterloo \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"University of Waterloo \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Research Insight LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lifitegrast","moa":"Integrin alpha-L\/beta-2 (LFA-1)","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Research Insight LLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Research Insight LLC \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Research Insight LLC \/ Inapplicable"},{"orgOrder":0,"company":"State University of New York College of Optometry","sponsor":"Novartis Pharmaceuticals Corporation | Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lifitegrast","moa":"Integrin alpha-L\/beta-2 (LFA-1)","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"State University of New York College of Optometry","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"State University of New York College of Optometry \/ Novartis Pharmaceuticals Corporation | Bausch & Lomb Incorporated","highestDevelopmentStatusID":"11","companyTruncated":"State University of New York College of Optometry \/ Novartis Pharmaceuticals Corporation | Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Richard W Yee, MD","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lifitegrast","moa":"Integrin alpha-L\/beta-2 (LFA-1)","graph1":"Immunology","graph2":"Phase I","graph3":"Richard W Yee, MD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Richard W Yee, MD \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Richard W Yee, MD \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Beijing Tongren Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lifitegrast","moa":"Integrin alpha-L\/beta-2 (LFA-1)","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lunan Pharmaceutical \/ Beijing Tongren Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Lunan Pharmaceutical \/ Beijing Tongren Hospital"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lifitegrast","moa":"Integrin alpha-L\/beta-2 (LFA-1)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lifitegrast","moa":"Integrin alpha-L\/beta-2 (LFA-1)","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Lifitegrast","moa":"Integrin alpha-L\/beta-2 (LFA-1)","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Lifitegrast

    Menu

    Lifitegrast

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bausch & Lomb Incorporated

                            Canada arrow
                            ESCRS
                            Not Confirmed

                            Bausch & Lomb Incorporated

                            Canada arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease

                            Details : Lifitegrast is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 19, 2025

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bausch & Lomb Incorporated

                            Canada arrow
                            ESCRS
                            Not Confirmed

                            Bausch & Lomb Incorporated

                            Canada arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lifitegrast/Perfluorohexyloctane Safety In Dry Eye Disease

                            Details : Lifitegrast is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 08, 2025

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Qilu Pharmaceutical

                            China arrow
                            ESCRS
                            Not Confirmed

                            Qilu Pharmaceutical

                            China arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lifitegrast Eye Drops in Healthy Subjects：Phase I Study

                            Details : Lifitegrast is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 27, 2025

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lunan Pharmaceutical

                            China arrow
                            ESCRS
                            Not Confirmed

                            Lunan Pharmaceutical

                            China arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Beijing Tongren Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 17, 2025

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Beijing Tongren Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bausch & Lomb Incorporated

                            Canada arrow
                            ESCRS
                            Not Confirmed

                            Bausch & Lomb Incorporated

                            Canada arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®

                            Details : The financing will fund the acquisition Xiidra (lifitegrast ophthalmic solution), a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalm...

                            Product Name : Xiidra

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 09, 2023

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            ESCRS
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Bausch & Lomb Incorporated

                            Deal Size : $2,500.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Novartis Completes Divestment of ‘Front of Eye’ Ophthalmology Assets

                            Details : Novartis will focus on other therapeutic areas, like retinal diseases via platforms including gene therapy and optogenetics through divestment of Xiidra (lifitegrast), the first approved treatment for dry eye disease, and SAF312 (libvatrep), for chronic ...

                            Product Name : Xiidra

                            Product Type : Other Small Molecule

                            Upfront Cash : $1,750.0 million

                            September 29, 2023

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Bausch & Lomb Incorporated

                            Deal Size : $2,500.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            ESCRS
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Bausch & Lomb Incorporated

                            Deal Size : $2,500.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Novartis Signs Agreement to Divest Front of Eye Ophthalmology Assets in Line with Focused Strategy

                            Details : Novartis will focus on other therapeutic areas, like retinal diseases via platforms including gene therapy and optogenetics through divestment of Xiidra (lifitegrast), the first approved treatment for dry eye disease, and SAF312 (libvatrep), for chronic ...

                            Product Name : Xiidra

                            Product Type : Other Small Molecule

                            Upfront Cash : $1,750.0 million

                            June 30, 2023

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Bausch & Lomb Incorporated

                            Deal Size : $2,500.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            State University of New York College of Optometry

                            Country arrow
                            ESCRS
                            Not Confirmed

                            State University of New York College of Optometry

                            Country arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Novartis Pharmaceuticals Corporation | Bausch & Lomb Incorporated

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 17, 2022

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Novartis Pharmaceuticals Corporation | Bausch & Lomb Incorporated

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Kedalion Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Kedalion Therapeutics

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Novartis Acquires Kedalion Therapeutics and Its Innovative Ocular Delivery Platform that Could Transform Patie...

                            Details : Novartis intends to develop the AcuStream technology for potential use with its existing and future front-of-eye therapies, which could include Xiidra® (lifitegrast ophthalmic solution) 5%, a first-in-class prescription LFA 1 antagonist for the treatmen...

                            Product Name : Xiidra

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 30, 2022

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Richard W Yee, MD

                            Country arrow
                            ESCRS
                            Not Confirmed

                            Richard W Yee, MD

                            Country arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 11, 2021

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth